Althea CEO & Managing Director Josh Fegan, said: “The launch of Althea Concierge UK and progression of our partnerships with two leading UK scientific committees are key developments for our UK expansion. While Althea Concierge UK streamlines prescribing pathways for doctors, the partnerships with Drug Science and IOTOD are furthering our educational outreach efforts. Althea is a global medicinal cannabis company and our strategy reflects that. We look forward to continued growth and replicating our highly successful Australian-born strategy abroad, working closely with doctors to provide patients the opportunity to choose an Althea life.”
The Althea Concierge medical education platform, which was launched in Australia in September 2018, provides medical education and clinical evidence for healthcare professionals looking to prescribe medicinal cannabis. The platform supports Althea UK’s entry to the market by streamlining the prescription process and facilitate patient referrals from primary care doctors to Althea UK specialist prescribers. The strategy is being leveraged from Althea’s successful Australian operations, which has seen significant and sustained increases in patient numbers that are rapidly approaching the 1,000 patient milestone.
Althea Concierge UK is now live at: https://concierge.althea.co.uk
MELBOURNE, Australia, May 31, 2019 /PRNewswire/ —
- Althea Concierge UK launched successfully with doctors already commencing their first assessments of patients for Althea medical cannabis products
- Althea Concierge UK streamlines the prescription process and facilitates patient referrals from primary care doctors to Althea UK specialist prescribers
- Althea and Drug Science joint educational meetings to be held in June are oversubscribed, with nearly 300 healthcare professionals registered to attend
- Althea sponsored and participated in the recent IOTOD conference in Germany
United Kingdom, 31 May 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX: AGH), through its wholly-owned subsidiary, Althea MMJ UK Ltd (‘Althea’ or ‘the Company’), is pleased to announce the launch of Althea Concierge UK and the progression of its partnerships with Drug Science and the Improving Outcomes in the Treatment of Opioid Dependence (IOTOD) scientific committees.
About Althea Group Holdings Limited (ASX:AGH)
Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.
Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe. To learn more, please visit: www.althea.life
Partnership with Drug Science Progresses
In further support of Althea’s UK expansion, the Company recently announced a partnership with Drug Science, the UK’s only completely independent scientific committee on drugs.
Althea has provided Drug Science with educational grant which will allow the non-profit to use Althea’s recently launched Medical Education In Cannabinoids learning portal (MEDIC) to educate healthcare professionals about medicinal cannabis.
Althea and Drug Science’s joint medical education meetings in London and Birmingham have attracted 200 and 69 registrations respectively, just five days after being publicized.
The meetings will be held in London on June 11th and Birmingham on June 12th and will include presentations from Drug Science founder Professor David Nutt, and Canadian prescribers with international credibility.
Sponsored and participated in IOTOD conference
In response to the significant educational gap in the UK, Althea is successfully collaborating with the IOTOD scientific committee.
Through an independent grant to the IOTOD, Althea facilitated the training of 265 European healthcare professionals at the IOTOD 2019 annual educational meeting in Frankfurt this month.
The IOTOD conference is an annual, Continuing Medical Education-accredited, two-day event developed in partnership with internationally renowned and leading opioid dependency experts. The conference attracts a multitude of specialists from across the globe and provided Althea with the opportunity to gain increased exposure in Europe due to its location and European focus.
Althea supported the event with a satellite session on medicinal cannabis hosted by Dr Sana-Ara Ahmed, a practicing Anesthesiologist, Interventional Pain and Cannabinoid Medicine Specialist based in Canada.
Source: Bloomberg; Althea Life